# Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

*PRI Rank #14 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-14*

| Field | Value |
| --- | --- |
| Rank | #14 |
| 18m citations | 33 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.01500 |
| Corresponding authors | Miguel Martín |
| Institution | Hospital Gregorio Marañón, Spain |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1200/jco.23.01500](https://doi.org/10.1200/jco.23.01500)

## Topics

giredestrant · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · acelERA BC study · physician's choice of endocrine monotherapy · fulvestrant · aromatase inhibitor · Progression-free survival · ESR1 mutation · circulating tumor DNA · CDK4/6 inhibitor · GnRH agonist · visceral disease · selective estrogen receptor degrader

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```